Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Alpha-1A-adrenoceptor** and **Alpha-1D-adrenoceptor** are closely related subtypes of the alpha-1 adrenergic receptor family, **G protein-coupled receptors** activated by catecholamines such as norepinephrine and epinephrine[5][4][3]. The α1A is prominent in the prostate, lower urinary tract, and certain vascular and neuronal tissues, mediating smooth muscle contraction involved in urinary tract function and vascular tone[7][4]. The α1D subtype predominates in specific vascular beds such as human epicardial coronary arteries, mediating vasoconstriction and contributing to blood pressure regulation[2][3]. Both subtypes are therapeutic targets for selective α1-blockers, which are used for hypertension and benign prostatic hyperplasia[5][2][4]. Ambiguous combined terms like "alpha-1A/1D adrenoceptor" are sometimes used to describe drugs or tissues where both subtypes are relevant, but for structured data, each should be handled separately as **Alpha-1A-adrenoceptor** and **Alpha-1D-adrenoceptor**[1][3][9]. **Note:** The target as presented, "alpha-1A/1D adrenoceptor," is **ambiguous/incorrect** for a canonical form because it attempts to merge two distinct, though related, subtypes. For structured databases, it is best to resolve to the two standard entities: "Alpha-1A-adrenoceptor" and "Alpha-1D-adrenoceptor."[3][9][1]
Antagonism (blockade) of α1A and/or α1D-adrenoceptor to cause smooth muscle relaxation (vasodilation, decreased peripheral resistance, relief of urinary tract obstruction) - Inhibition of vasoconstrictive effects mediated by norepinephrine/epinephrine[5][2][4]
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-1A-adrenoceptor and Alpha-1D-adrenoceptor (α1A-adrenoceptor, α1D-adrenoceptor).